Evelo Bioscience, a biotech company based on UChicago-licensed technology, debuts on Nasdaq
Evelo Biosciences, a biotechnology company dedicated to improving the lives of patients globally through the development of a new modality of medicines called monoclonal microbials, made their debut on Nasdaq today. Evelo, which is based in Cambridge, Massachusetts, is developing therapeutics arising from the work of Dr. Thomas Gajewski, the AbbVie Foundation Professor of Cancer Immunotherapy at the University of Chicago. Gajewski found that gut bacteria can affect the efficacy and potency of some immunotherapies, and that the introduction of a particular strain of bacteria into the digestive tracts of mice with melanoma boosted the ability of the animal’s immune system to attack tumor cells. When combined with a checkpoint blockade inhibitor against PD-L1, the therapy nearly eradicated tumors in the mice.
Evelo has a worldwide, exclusive license to this technology from the University of Chicago, which was executed by the Polsky Center for Entrepreneurship and Innovation.